Highlights

MWC continues to lead the way in NZ cancer vaccine research

MWC continues to lead the way in NZ cancer vaccine research

Immune therapy is one of the most exciting and promising areas of cancer research. Around New Zealand, teams of Maurice Wilki...

read the full story

New imaging improves our understanding of the immune system

New imaging improves our understanding of the immune system

Maurice Wilkins Centre researchers have used novel imaging technology to reveal the structure and inner workings of entire ly...

read the full story

Building blocks for new medicines

Building blocks for new medicines

The MWC uses New Zealand’s outstanding medicinal chemistry expertise to discover new medicines. A particular kind of chemistr...

read the full story

One cancer gene – but several different proteins

One cancer gene – but several different proteins

Cancer arises due to changes in DNA in a single cell.  Many changes are needed over time to a cell’s DNA to make it cancerous...

read the full story

Turning the tables on cancer

Turning the tables on cancer

Tumours often contain areas with less oxygen than is found in normal tissues. These areas are less vulnerable to many forms o...

read the full story

Mid-term review sets future direction

Mid-term review sets future direction

A comprehensive independent assessment found the Centre to be performing at a high level, producing distinct and positive ben...

read the full story

Smarter drug design

Smarter drug design

An advanced experimental technique linked to high powered computation is becoming an increasingly important tool for MWC rese...

read the full story

MWC welcomes landmark results for lung cancer drug

MWC welcomes landmark results for lung cancer drug

A novel lung cancer drug with strong development links to the MWC has shown impressive results in a large-scale international...

read the full story

Newly funded research highlights MWC collaborations

Newly funded research highlights MWC collaborations

A five-year research programme aims to develop nontoxic vaccine technologies to complement existing cancer immunotherapies.

read the full story